Potential PAH Therapy, KER-012 Also Prevents Bone Loss in Rat Model

Potential PAH Therapy, KER-012 Also Prevents Bone Loss in Rat Model

308303

Potential PAH Therapy, KER-012 Also Prevents Bone Loss in Rat Model

A lab version of an investigational treatment for bone disorders and pulmonary arterial hypertension (PAH), KER-012 prevented bone loss in a PAH rat model, its developer, Keros Therapeutics, reported. Separate preclinical data in a PAH rat model, presented by the company earlier this year, also demonstrated that KER-012 worked to block increases in inflammation, fibrosis (scarring), and heart damage in the animals. As such, it showed a “potential to treat PAH in patients without dose-limiting increases in red blood cells,”…

You must be logged in to read/download the full post.